價(jià)格 | 詢價(jià) | ||
包裝 | 100ug | 500ug | 1000ug |
最小起訂量 | 100ug |
發(fā)貨地 | 北京 |
更新日期 | 2024-12-16 |
中文名稱:Fusion glycoprotein蛋白 | 英文名稱:Fusion glycoprotein |
品牌: 百普賽斯 | 產(chǎn)地: 北京 |
保存條件: -20°C to -70°C | 純度規(guī)格: 99.9% |
產(chǎn)品類別: 重組蛋白 | |
貨號(hào): Fusion glycoprotein | 用途范圍: 藥物開發(fā)等 |
規(guī)格: 100ug | 是否進(jìn)口: 否 |
英文名稱:Respiratory syncytial virus F protein
中文名稱:呼吸道合胞病毒F蛋白
靶點(diǎn)別稱:Fusion glycoprotein,F protein,Nipah virus,Hendra virus
物種:Nipah virus
屬性:Protein
標(biāo)記:Unconjugated
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.
成立日期 | 2010-07-22 (15年) | 注冊(cè)資本 | 8000萬(wàn)人民幣 |
員工人數(shù) | 500人以上 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 醫(yī)藥中間體,原料藥,激素類,氨基糖苷類,中樞神經(jīng)系統(tǒng)用藥 | 經(jīng)營(yíng)模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP3年
|
武漢佰樂博生物技術(shù)有限公司
|
2024-12-27 | |
¥1098 |
VIP3年
|
上海滬震實(shí)業(yè)有限公司
|
2024-12-30 | |
¥6940.00 |
VIP9年
|
北京索萊寶科技有限公司
|
2024-12-27 |